Makes all biosimilar drugs automatically swappable

Congress file s1954-119, before Congress. Still to be decided as of 2026-07-27.

Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.

What it does

Pharmacists can swap biosimilars at the counter When you fill a prescription, your pharmacist can now replace the brand-name drug with any approved biosimilar copy without extra paperwork, which may lower your out-of-pocket cost if your insurance covers the cheaper version.

The bigger picture

Competition could speed up and lower drug prices With fewer hurdles to approval, more biosimilar makers can enter the market faster, and more choice typically pushes prices down for all versions of the drug.

What to watch

First movers keep short protection from new rivals The first biosimilar company to win approval for a drug keeps its head start and block-out period, but only if that period hasn't expired yet; after it ends, new biosimilars enter immediately without waiting.

Official summary

This bill deems all biosimilars licensed by the Food and Drug Administration (FDA) interchangeable with their reference products.A biosimilar is a biological product (e.g., a drug or vaccine) that is very similar to a brand-name biological product (i.e., the reference product). Under current law, a biosimilar that meets additional requirements may be deemed interchangeable with the reference product; this designation allows pharmacists to substitute the interchangeable biosimilar when filling a prescription for the reference product, depending on state law. Further, the first biosimilar deemed interchangeable with a given reference product is awarded a period of marketing exclusivity.The bill eliminates additional requirements for demonstrating interchangeability so that all licensed biosimilars are deemed interchangeable with their reference products. (Draft guidance released by the FDA in 2024 proposed to make some of these interchangeability requirements optional, including studies related to the safety of switching between use of the biosimilar and reference product. It has not been finalized.)This change takes effect 60 days after the bill is enacted, and previously licensed b

Read the official record for s1954-119

See everything up for a vote · This week in Congress · See what we have filed with the clerk